David M. Jackman

Oncology

300 Boylston St
Chestnut Hill, MA 02467

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC): A Randomized Clinical Trial.

Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC): A Randomized Clinical Trial.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: June 26, 2025

Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U.

Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U.

Journal: JCO precision oncology

Published: December 18, 2024

Using Oncology Treatment Pathway Data to Evaluate Serious Illness Communication, Care Utilization, and End-of-Life Care for Patients With Cancer.

Using Oncology Treatment Pathway Data to Evaluate Serious Illness Communication, Care Utilization, and End-of-Life Care for Patients With Cancer.

Journal: JCO oncology practice

Published: September 30, 2024

Early Findings on the Use of Clinical Pathways for Management of Unwarranted Variation in Cancer Care.

Early Findings on the Use of Clinical Pathways for Management of Unwarranted Variation in Cancer Care.

Journal: American journal of medical quality : the official journal of the American College of Medical Quality

Published: June 10, 2021

Lessons from the front: designing and implementing clinical pathways by and for clinicians.

Lessons from the front: designing and implementing clinical pathways by and for clinicians.

Journal: The American journal of managed care

Published: February 21, 2020

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.

Journal: The oncologist

Published: October 15, 2018

Implementation to Optimization: A Tailored, Data-Driven Approach to Improve Provider Efficiency and Confidence in Use of the Electronic Medical Record.

Implementation to Optimization: A Tailored, Data-Driven Approach to Improve Provider Efficiency and Confidence in Use of the Electronic Medical Record.

Journal: Journal of oncology practice

Published: June 26, 2018

Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.

Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 11, 2018

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 24, 2018

Cost and Survival Analysis Before and After Implementation of Dana-Farber Clinical Pathways for Patients With Stage IV Non-Small-Cell Lung Cancer.

Cost and Survival Analysis Before and After Implementation of Dana-Farber Clinical Pathways for Patients With Stage IV Non-Small-Cell Lung Cancer.

Journal: Journal of oncology practice

Published: March 07, 2017

Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial.

Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial.

Journal: JAMA oncology

Published: July 09, 2016

Radiologic-pathologic correlation of response to chemoradiation in resectable locally advanced NSCLC.

Radiologic-pathologic correlation of response to chemoradiation in resectable locally advanced NSCLC.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 03, 2016

Showing 1-12 of 43

Last Updated: 09/26/2026